Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Omeros Corporation - Common Stock (NQ:OMER)

3.090 -0.230 (-6.93%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Omeros Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Omeros Corporation to Announce First Quarter Financial Results on May 10, 2022
From Omeros Corporation
Via Business Wire
Omeros Announces Journal of Clinical Oncology Publication Detailing Pivotal Trial Results for Narsoplimab in HSCT-TMA
From Omeros Corporation
Via Business Wire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Adagio Therapeutics (NASDAQ:ADGI) shares increased by 52.2% to $5.86 during Wednesday's pre-market session. The company's market cap stands at $651.9 million. 
Via Benzinga
Earnings Scheduled For March 1, 2022
Companies Reporting Before The Bell • Precigen (NASDAQ:PGEN) is expected to report earnings for its fourth quarter. • TG Therapeutics (NASDAQ:TGTX) is estimated... 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
Tuesday morning saw 454 companies set new 52-week lows. Interesting Facts About Today's 52-Week Lows: Unilever (NYSE:UL) was the largest firm by market cap to set a... 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
On Thursday, 236 companies hit new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 160 companies hit new 52-week lows. Areas of Significance In Today's 52-Week Lows: Walt Disney (NYSE:DIS) was the largest firm by market cap to set a new... 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
On Tuesday, 242 companies hit new 52-week lows. Noteworthy Mentions In Today's 52-Week Lows: The largest company in terms of market cap to set a new 52-week low was... 
Via Benzinga
Omeros's Return On Capital Employed Insights
According to Benzinga Pro, during Q4, Omeros (NASDAQ:OMER) earned $280.62 million, a 1336.05% increase from the preceding quarter. Omeros also posted a total of $30.84 million in... 
Via Benzinga
Omeros: Q4 Earnings Insights
Omeros (NASDAQ:OMER) reported its Q4 earnings results on Tuesday, March 1, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Omeros missed... 
Via Benzinga
Omeros Corporation to Announce Fourth Quarter and Year-end Financial Results on March 1, 2022
From Omeros Corporation
Via Business Wire
The Daily Biotech Pulse: Novavax COVID Shot Authorized In Australia, Zymeworks Restructures, Orphan Drug Designation For Marker's Pancreatic Cancer Drug
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Eisai Announces Publication Of Positive Data On Lenvima-Keytruda Combo In... 
Via Benzinga
Omeros Submits Response To FDA Regarding Narsoplimab Application In HSCT-TMA
Omeros Corporation (NASDAQ: OMER) has submitted to the FDA its response to Complete Response Letter for narsoplimab in hematopoietic stem cell transplant-associated... 
Via Benzinga
Omeros Confirms Submission of Response to FDA Regarding the BLA for Narsoplimab in the Treatment of HSCT-TMA
From Omeros Corporation
Via Business Wire
Omeros Completes Sale of OMIDRIA® Franchise to Rayner Surgical
From Omeros Corporation
Via Business Wire
Omeros Corporation (NASDAQ:OMER) Investor Notice: Investigation over Potential Wrongdoing
San Diego, CA -- (SBWIRE) -- 12/14/2021 -- Certain directors of Omeros Corporation are under investigation over potential breaches of fiduciary duties. 
Via SBWire
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Applied DNA Sciences (NASDAQ:APDN... 
Via Benzinga
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Omeros Corporation and Encourages Investors with Losses to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal Product Safety
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Lixte Biotech Holdings (NASDAQ:LIXT 
Via Benzinga
Omeros Offloads Cataract Med Omidria To Rayner Surgical In Deal Valued Over $1B
Omeros Corporation (NASDAQ: OMER) has agreed to sell Omidria to Rayner Surgical Group Limited for an upfront payment of $125 million with an additional $200... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Omeros (NASDAQ:OMER) stock increased by 15.68% to $7.89 during Thursday's pre-market session. The market value of their outstanding shares is at $493.4 million... 
Via Benzinga
Omeros Announces Agreement to Sell OMIDRIA® Franchise to Rayner Surgical in a Transaction Valued in Excess of $1 Billion
From Omeros Corporation
Via Business Wire
Omeros: Q3 Earnings Insights
Omeros (NASDAQ:OMER) reported its Q3 earnings results on Tuesday, November 9, 2021 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Omeros... 
Via Benzinga
Omeros Corporation Reports Third Quarter 2021 Financial Results
From Omeros Corporation
Via Business Wire
76 Biggest Movers From Yesterday
Gainers Expensify, Inc. (NASDAQ: EXFY) jumped 52.1% to settle at $41.06 on Wednesday after the company priced its IPO at $27 per share. RenovoRx, Inc. (NASDAQ: RNXT) shares... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
Earnings Outlook For Omeros
Omeros (NASDAQ:OMER) is set to give its latest quarterly earnings report on Tuesday, 2021-11-09. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Antitrust Nod For Acceleron Deal In Germany, Austria, Announces... 
Via Benzinga
Omeros' Narsoplimab Shows Improved, Stabilized Renal Function At Three Years
Omeros Corporation (NASDAQ: OMER) announced long-term follow-up (35 months) results from the Phase 2 trial of its MASP-2 inhibitor narsoplimab in patients with IgA... 
Via Benzinga
Omeros Announces Results From Nearly Three-Year Follow-up of Patients in Phase 2 IgA Nephropathy Trial
From Omeros Corporation
Via Business Wire
Omeros’ Narsoplimab Stabilized Kidney Function and Reduced Urinary Complement Proteins in a Patient with IgA Vasculitis
From Omeros Corporation
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.